David Bottomley

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

David P. Dearnaley, Matthew R. Sydes, John D. Graham et al. · The Lancet Oncology · 2007 · 908 citations

Medicine, Oncology, Radiation Oncology +17

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

David P. Dearnaley, Gordana Jovic, Isabel Syndikus et al. · The Lancet Oncology · 2014 · 462 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

Peter Hoskin, Oliver Sartor, Joe M. O’Sullivan et al. · The Lancet Oncology · 2014 · 407 citations

Medicine, Oncology, Pharmacology +17

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

Christopher Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2020 · 403 citations · Full text

Medicine, Radiation Oncology, Urology +11